Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy.
To date, in utero bone marrow transplantation (BMT) has had limited success, largely because of poor donor engraftment. The poor engraftment is probably the result of performing the procedure late in gestation after significant fetal immunocompetence has developed and/or transplanting insufficient numbers of donor hematopoietic stem cells for competing successfully with ongoing fetal hematopoiesis. To overcome these problems, we performed in utero BMT on a fetus with globoid cell leukodystrophy during the first trimester of gestation using selected paternal bone marrow stem (CD34+) cells. CD34 selection allowed a substantially greater number of stem cells to be transplanted. Although the fetus died 7 weeks after the procedure (during the 20th week of gestation), full donor engraftment was established. Moreover, the cause of death appeared to be overwhelming donor engraftment and leukostasis with paternal myeloid cells infiltrating most tissues. The ability of in utero BMT to produce this degree of engraftment provides great promise for the use of this approach in the treatment of a variety of inherited disorders that can be diagnosed prenatally.
Bambach
B J
BJ
Oncology Center's Bone Marrow Transplantation Program, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Moser
H W
HW
Blakemore
K
K
Corson
V L
VL
Griffin
C A
CA
Noga
S J
SJ
Perlman
E J
EJ
Zuckerman
R
R
Wenger
D A
DA
Jones
R J
RJ
D016026:Bone Marrow Transplantation; D005260:Female; D005315:Fetal Diseases / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007965:Leukodystrophy, Globoid Cell / Q000628:therapy*; D008297:Male; D011247:Pregnancy